据港交所官网，山东信得科技股份有限公司（以下简称"信得科技"）日前首次向港交所呈交了IPO（首次公开募股）申请文件，工 银国际和中泰国际为联席保荐人。据招股书（申请版本，下同），信得科技拟将此次港股IPO募集资金用于研发计划及扩展产品组 合、扩大产能、拓展海外市场以及营运资金及其他一般公司用途。 《每日经济新闻》记者（以下简称"每经记者"）注意到，尽管信得科技称其在中国动物保健市场中排名靠前，但该行业面临激烈 的竞争，且客户在兽用生物制品及药物采购方面的议价能力提升，或影响其盈利能力。此外，信得科技在2024年因抗体产品的平 均售价下降导致收入和利润"双降"。值得一提的是，信得科技的估值在C轮融资过后达到约18亿元，但较B轮融资及于2022年8月进 行的股份转让后的约28.78亿元的估值缩水了近四成。 客户议价能力提升或降低公司盈利能力 信得科技成立于1999年，是中国一家动物保健企业，其主要从事全系列动物保健及配套产品的研发、生产及销售，产品涵盖兽用 生物制品（如疫苗、抗体、转移因子等）、中兽药、化药制剂、动物饲料及饲料添加剂，实现对家禽、家畜、水产动物及宠物疾 病的预防、诊断、治疗与控制。 招股书援引灼识 ...

资料显示，中牧实业股份有限公司位于北京市丰台区南四环西路188号八区16-19号楼，成立日期1998年 12月25日，上市日期1999年1月7日，公司主营业务涉及动物保健品,包括畜禽用疫苗、诊断液、兽药等 几大类。动物营养品:包括饲料原料、饲料添加剂、预混合饲料及大宗饲料原料的进出口贸易。主营业 务收入构成为：化药35.78%，贸易27.87%，饲料19.21%，生物制品16.10%，其他1.04%。 中牧股份所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：禽流感药物、兽 药、年报预增、宠物经济、病毒防治等。 2月24日，中牧股份盘中上涨2.09%，截至13:43，报7.83元/股，成交6372.50万元，换手率0.80%，总市 值79.96亿元。 资金流向方面，主力资金净流入208.71万元，特大单买入755.45万元，占比11.85%，卖出151.59万元， 占比2.38%；大单买入1138.46万元，占比17.87%，卖出1533.62万元，占比24.07%。 中牧股份今年以来股价跌0.51%，近5个交易日跌1.26%，近20日跌7.77%，近60日跌0.13%。 机构持仓方面，截止 ...

------广告------ 动物保健行业头部企业，中国禽用兽用生物制品排名第三的供应商，2025年收入利润双增的信得科技赴港上市。 智通财经APP了解到，近日信得科技向港交所主板递交上市申请书，工银国际、中泰国际为其联席保荐人。该公司是中国领先的动物 保健企业，根据灼识咨询的资料，以2024年收入计，该公司以1.4%的市场份额在中国动物保健市场中排名第九，并以7.9%的市场份额 在中国禽用兽用生物制品市场排名前三。 从业务上看，该公司经营兽用生物制品，其中包括疫苗产品、抗体产品及转移因子、化药制剂、饲料及饲料添加剂及中兽药产品。疫 苗产品占收入大头，2024年及2025年前9月该产品收入保持增长，收入份额分别为48.5%及53.8%，其次化药制剂，产品收入也呈增长趋 势，期间收入份额分别为20.3%及16%。此外， 2025年前9月，抗体产品、转移因子、饲料及饲料添加剂及中兽药产品收入份额分别为 7.6%、7.7%、5.7%及2.8%。 | | | 截至12月31日止年度 | | | | 截至9月30日止九個月 | | | | --- | --- | --- | --- | --- | --- | --- ...

动物保健行业头部企业，中国禽用兽用生物制品排名第三的供应商，2025年收入利润双增的信得科技赴港上市。 | | | 截至12月31日止年度 | | | | 截至9月30日止九個月 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 2023年 | | 2024年 | | 2024年 | | 2025年 | | | 人民幣千元 | % - | 人民幣千元 | % | 人民幣千元 | 6 | 人民幣千元 | | 獸用生物製品 | | | | | | | | | 疫苗產品 | 464.952 | 47.2 | 476.267 | 48.5 | 346.917 | 49.5 | 471.332 | | 抗體產品 | 96,414 | 9.8 | 86,230 | 8.8 | 63,470 | 9.1 | 66,797 | | 轉移因子 | 64.948 | 6.6 | 68,033 | 6.9 | 47.317 | 6.8 | 67.282 | | 小計 | 626.314 | 63.6 | 630.530 | 64.2 | 457.704 | 65.4 ...

Core Viewpoint - Shandong Xinde Technology Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange for a main board listing, aiming to expand its production capacity and enhance R&D in new vaccines and pet medications [2][4] Company Overview - Founded in 1999 and registered in Weifang, Shandong, Xinde Technology is a leading animal health company in China, focusing on the R&D, production, and sales of veterinary biological products, traditional Chinese veterinary medicine, chemical drug formulations, feed, and feed additives [2] - The company ranks 9th among domestic manufacturers in China's animal health market with a market share of approximately 1.4%, and is among the top three in the poultry veterinary biological products market [2] Financial Performance - For the years 2023, 2024, and the first nine months of 2025, the company's revenue was reported at 985 million yuan, 982 million yuan, and 877 million yuan respectively, with gross profit margins of 49.7%, 50.8%, and 55.3% [2] - Net profits for the same periods were 34.76 million yuan, 28.12 million yuan, and 55.67 million yuan [2] - Overseas revenue has seen significant growth, increasing from 12.2 million yuan in 2023 to 46.1 million yuan in the first nine months of 2025, with products entering markets such as Pakistan, Egypt, and Vietnam [2] Strategic Initiatives - The company plans to use the funds raised from the IPO primarily to expand its production base and capacity, enhance R&D investment in new vaccines and pet medications, and expand its domestic and international sales networks [4] - The controlling shareholder is Chairman and President Li Chaoyang, who holds 45.08% of the voting rights, with Sumitomo Corporation, a Fortune Global 500 company, as a strategic shareholder [4]

动物保健行业头部企业，中国禽用兽用生物制品排名第三的供应商，2025年收入利润双增的信得科技赴港上市。 智通财经APP了解到，近日信得科技向港交所主板递交上市申请书，工银国际、中泰国际为其联席保荐人。该公司是中国领先的动物保健企业，根据灼识咨 询的资料，以2024年收入计，该公司以1.4%的市场份额在中国动物保健市场中排名第九，并以7.9%的市场份额在中国禽用兽用生物制品市场排名前三。 信得科技主要从事全系列动物保健及配套产品的研发、生产及销售，旗下有20家子公司，其中旗下5家子公司在经营中作出重大贡献，分别是北京信得、山 东海利、青岛信得、山东信得及青岛幸福。在业绩上，2024年及2025年前九月，收入分别增长-0.3%及25.2%，盈利能力较低，净利率分别为2.8%及6.3%。 动物保健市场规模增长较缓，根据灼识咨询，2024年全球动物保健行业市场规模511亿美元（按即时汇率为3525.9亿元人民币），近五年复合增速仅为 4.9%，中国市场规模为680亿元，复合增长仅为6%。行业前景一般，但该公司积极扩张全球市场，截止2025年9月，该公司拥有现金及等价物1.37亿元。 图片来源：公司聆讯资料 信得科技通 ...

Investment Rating - The report maintains a "Recommendation" rating for the veterinary medicine industry, expecting the industry index to outperform the benchmark index by more than 5% in the next 3-6 months [80]. Core Insights - In January, the majority of vaccine varieties saw a year-on-year decline in batch approvals, with the Veterinary Product Index (VPI) dropping 1.8% month-on-month, marking three consecutive months of decline [2][3]. - The report highlights that the overall performance of the animal vaccine and veterinary medicine sector has been affected by high base effects from the previous year, low breeding sentiment, and the timing of the Spring Festival impacting stocking rhythms [10][57]. - The report emphasizes the importance of innovation in driving performance, noting that companies demonstrating product, marketing, or capital operation innovations have shown better financial results [71][72]. Summary by Sections Vaccine Batch Approvals - In January, most vaccine products experienced a year-on-year decline in batch approvals. For pig vaccines, the majority saw declines, with only pseudorabies and blue ear vaccines showing increases of 13.1% and 30.2%, respectively. Other vaccines like foot-and-mouth disease and porcine circovirus vaccines saw declines ranging from 20% to 50% [9][10]. - In the poultry vaccine segment, the H5N1 trivalent vaccine and Marek's vaccine saw declines of 13.8% and 25.9%, respectively, while the newcastle disease vaccine remained flat [9][10]. Veterinary Raw Materials - The VPI index averaged 66.16 in January, down 1.8% from December, with a continued downward trend observed in the prices of most raw materials. For instance, the price of florfenicol dropped by 4.5% month-on-month, while amoxicillin saw a slight increase of 0.7% [57][58]. - Year-on-year comparisons show that while some products like tylosin and tilmicosin have seen significant price increases, amoxicillin has dropped by 28.8% [58][57]. Investment Recommendations - The report suggests focusing on undervalued companies with improvement logic, highlighting that the ongoing industry competition has led to a market environment where only innovative companies are likely to thrive. Recommended companies include Zhongmu Co., Ltd., Reap Bio, and others [71][73].

Group 1: New Listings and Market Developments - Four companies, including Shandong Xinde Technology Co., Ltd., Shanghai Goraili Software Co., Ltd., Shenzhen Delan Minghai New Energy Co., Ltd., and Shenzhen Hongyeji Geotechnical Technology Co., Ltd., have submitted listing applications to the Hong Kong Stock Exchange, representing diverse sectors such as animal health, semiconductor software, portable energy storage, and geotechnical engineering [1] - Shanghai Shangmi Technology Group Co., Ltd. has passed the listing hearing at the Hong Kong Stock Exchange, positioning itself as a leading provider of Business Internet of Things (BIoT) solutions with over 10% market share in the Android-based BIoT sector [2] Group 2: Corporate Restructuring and Financial Stability - The Hong Kong High Court has rejected a winding-up petition against Country Garden, alleviating immediate delisting and liquidation risks, which indicates the court's recognition of the company's overseas debt restructuring plan [3] Group 3: Travel Industry Insights - Tongcheng Travel reported a significant increase in travel activity during the nine-day Spring Festival holiday, with a 38% rise in civil aviation travel compared to the same period last year, indicating a growing trend for segmented holiday travel [4]

Core Viewpoint - Shandong Xinde Technology Co., Ltd. has submitted its prospectus to the Hong Kong Stock Exchange for a main board listing, with ICBC International and Zhongtai International as joint sponsors [1] Company Overview - Established in 1999 and located in Weifang, Shandong, Xinde Technology is a leading animal health enterprise in China, focusing on the R&D, production, and sales of a full range of animal health products [3] - The product matrix includes veterinary biological products (vaccines, antibodies, transfer factors), traditional Chinese veterinary medicine, chemical drug formulations, feed, and feed additives, catering to the health management needs of poultry, livestock, aquatic animals, and pets [3] - The company has been recognized as a national enterprise technology center, a high-tech enterprise, and a specialized and innovative small giant enterprise by the Ministry of Industry and Information Technology [3] Market Position - According to ZhiShi Consulting, Xinde Technology ranks 9th among domestic manufacturers in China's animal health market with a market share of approximately 1.4% as of 2024, and it is among the top three in the poultry veterinary biological products market [3] - The company holds the leading market share in specific segments such as veterinary transfer factors, Newcastle disease vaccines, and avian mycoplasma vaccines [3] Technological Innovation - Xinde Technology emphasizes technological innovation, holding 12 national-level new veterinary drug approvals, 25 biological product approvals, and 21 traditional Chinese veterinary medicine approvals [5] - It is one of the first companies globally to use suspension culture technology for producing highly pathogenic avian influenza vaccines and has launched the first quadrivalent poultry vaccine in China [5] Production Capacity - The company has established four production bases in Shandong and Beijing, equipped with 34 production lines certified by the new veterinary drug GMP standards, and has invested 1.1 billion yuan in advanced manufacturing capacity [5] Financial Performance - The unaudited financial data shows that Xinde Technology achieved revenues of 985 million yuan, 982 million yuan, and 877 million yuan for the years 2023, 2024, and the first nine months of 2025, respectively [5] - Gross profits for the same periods were 456 million yuan, 452 million yuan, and 436 million yuan, with gross margins of 49.7%, 50.8%, and 55.3% [5] - The net profits for these periods were 34.76 million yuan, 28.12 million yuan, and 55.67 million yuan, indicating a steady improvement [5] International Expansion - Xinde Technology's overseas revenues were 12.2 million yuan, 28.3 million yuan, and 46.1 million yuan for the same periods, showing rapid growth, with products entering markets in Pakistan, Egypt, and Vietnam [5] - The company is also working on distributor registrations in 31 countries [5] Shareholding and Management - As of February 7, the controlling shareholder is the company's chairman and president, Li Chaoyang, who holds 45.08% of the voting rights [6] - Sumitomo Corporation, a Fortune Global 500 company, is a strategic shareholder [6] Industry Environment - The Chinese animal health industry is currently experiencing a dual track of policy tightening and market expansion, with the implementation of new veterinary drug GMP certifications accelerating industry reshuffling [6] - The market size for China's animal health sector is projected to reach 68 billion yuan in 2024, with a compound annual growth rate (CAGR) of 6.0% from 2019 to 2024, and expected to grow to 141 billion yuan by 2034 [6] - The global animal health market is estimated to be approximately 51.1 billion USD in 2024, with projections of reaching 85.8 billion USD by 2034 [6] Fundraising Purpose - Although specific amounts are not disclosed, the funds raised from the IPO will primarily be used to expand production bases and capacity, enhance R&D in new vaccines, chemical drugs, and pet medicines, and expand domestic and international sales networks [6] - The company aims to deepen its integrated development model of "mineral + energy," consolidate its domestic market advantage, accelerate overseas market penetration, and seize opportunities in emerging sectors such as pet economy and antibiotic-free farming [6]

Group 1 - The core viewpoint of the article is that Shandong Xinde Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to become a leading player in the animal health sector with a comprehensive industry chain and global perspective [1][3][5] Group 2 - Xinde Technology has established itself as a leader in the animal health industry, ranking among the top three in the core segment of avian veterinary biological products and holding a dominant position in several high-barrier niche markets [3][4] - The company has a strong research and development (R&D) platform, employing advanced technologies such as full suspension cell culture for producing high-pathogenic avian influenza vaccines, and has a team of 189 R&D personnel with over 60% holding master's degrees or higher [4] Group 3 - Financial performance has been robust, with a reported revenue of 877 million yuan for the first nine months of 2025, representing a year-on-year growth of 25.2%, and a pre-tax profit increase exceeding 100% [5] - The company's global strategy has led to explosive growth in overseas business, with overseas revenue reaching 46.1 million yuan, a year-on-year increase of 123.8% [5] Group 4 - The funds raised from the Hong Kong listing will be used to enhance R&D capabilities, expand advanced production capacity, and deepen global expansion efforts, with the goal of becoming a globally influential leader in animal health [7]